Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Abstract Background Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin aldosterone system (RAAS), particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium glucose cotransporte...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2021-10, Vol.42 (Supplement_1)
Hauptverfasser:	Neuen, B L, Oshima, M, Perkovic, V, Arnott, C, Bakris, G, Cannon, C P, Charytan, D M, Jardine, M, Levin, A, Neal, B, Pollock, C, Wheeler, D C, Mahaffey, K W, Heerspink, H J L
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!